消化器がんの世界市場レポート 2025年

消化器がん市場規模は、今後数年で急成長が見込まれます。2029年の年間平均成長率（CAGR）は11.9％で、424億5,000万米ドルに成長します。このような成長が予想される背景には、バイオマーカーに基づく治療法の適用拡大、がんの早期発見に関する一般市民の意識の高まり、ヘルスケアシステムの強化、がん治療に対する政府の支援プログラム、低侵襲治療技術への嗜好の高まりなどがあります。この期間に予測される主な市場動向には、診断技術の進歩、標的療法と免疫療法の画期的進歩、がん管理における人工知能の統合、精密医療研究の継続的進展などがあります。

標的療法の採用が増加していることが、今後の消化器がん市場の成長を促進すると予想されます。標的療法は、特定の分子標的に作用することでがん細胞の増殖を正確に阻害し、正常で健康な細胞への害を減らす治療法です。これらの治療法は、特にがんにおいて、病気を引き起こす特定の分子経路や遺伝子変異に作用するように設計されています。健康な細胞と病気の細胞の両方を攻撃する化学療法のような従来の治療とは異なり、標的療法は患者の病態の特異的な特徴に焦点を当てる。消化器（GI）がんの場合、標的療法は腫瘍の成長をコントロールする特定の遺伝子やタンパク質に作用し、正確で効果的な治療を可能にします。このアプローチは、従来の化学療法に比べて副作用が少なく、より良い治療結果をもたらします。例えば、米国を拠点とする専門家会員組織である米国遺伝子・細胞治療学会（ASGCT）と、米国を拠点とする医薬品・機器プロバイダーであるCiteline社によると、2023年7月、第1四半期（Q1）末までにフェーズII段階にある遺伝子治療は247件で、第2四半期（Q2）末までに5％増加して260件に達しました。そのため、標的療法の採用が増加しており、消化器がん市場の成長を牽引しています。

消化器がん市場で事業を展開する主要企業は、患者の生存率を向上させ、治療に関連する副作用を最小限に抑えるため、モノクローナル抗体治療などの先進ソリューションの開発に注力しています。モノクローナル抗体治療では、がん細胞を正確に識別して付着し、免疫系ががん細胞を標的として排除するのを補助する、実験室で作製された抗体を使用します。例えば、2024年9月、日本の製薬会社であるアステラス製薬株式会社は、フルオロピリミジンおよびプラチナ製剤を含む化学療法と併用するVYLOY（ゾルベツキシマブ）を発売し、欧州委員会から承認を取得しました。本剤は、クローディン18.2（CLDN18.2）を発現している切除不能または転移性の局所進行性HER2陰性胃または胃食道接合部（GEJ）腺がんの成人患者に対する一次治療薬です。今回の承認により、VYLOYは、SPOTLIGHT試験およびGLOW試験の良好な臨床試験データに基づき、これらの患者の約38%に存在するバイオマーカーであるCLDN18.2を標的とした欧州連合における最初で唯一の治療薬となります。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、貿易戦争と関税、そしてコロナ禍と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界の消化器がん：PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の消化器がん市場：成長率分析
• 世界の消化器がん市場の実績：規模と成長、2019年～2024年
• 世界の消化器がん市場の予測：規模と成長、2024年～2029年、2034年
• 世界の消化器がん：総潜在市場規模（TAM）

第6章 市場セグメンテーション

• 世界の消化器がん市場：がんタイプ別、実績と予測、2019年～2024年、2024年～2029年、2034年
• 大腸がん
• 胃がん
• 食道がん
• 膵臓がん
• 肝臓がん
• その他のがんタイプ
• 世界の消化器がん市場：診断別、実績と予測、2019年～2024年、2024年～2029年、2034年
• 内視鏡検査
• 生検
• 分子診断
• 画像診断
• その他の診断
• 世界の消化器がん市場：治療別、実績と予測、2019年～2024年、2024年～2029年、2034年
• 化学療法
• 免疫療法
• 標的療法
• 放射線治療
• 手術
• その他の治療
• 世界の消化器がん市場：エンドユーザー別、実績と予測、2019年～2024年、2024年～2029年、2034年
• 病院
• 腫瘍学センター
• 研究機関
• 診断検査室
• その他のエンドユーザー
• 世界の消化器がん市場、大腸がんの種類別サブセグメンテーション、実績と予測、2019年～2024年、2024年～2029年、2034年
• 大腸がん
• 直腸がん
• 再発性大腸がん
• 転移性大腸がん
• 世界の消化器がん市場、胃がんの種類別サブセグメンテーション、実績と予測、2019年～2024年、2024年～2029年、2034年
• 腺がん
• 消化管間質腫瘍（GIST）
• リンパ腫
• カルチノイド腫瘍
• 世界の消化器がん市場、食道がんの種類別サブセグメンテーション、実績と予測、2019年～2024年、2024年～2029年、2034年
• 腺がん
• 扁平上皮がん
• 小細胞がん
• その他のまれな食道腫瘍
• 世界の消化器がん市場、膵臓がんの種類別サブセグメンテーション、実績と予測、2019年～2024年、2024年～2029年、2034年
• 外分泌膵臓がん
• 内分泌（神経内分泌）膵臓腫瘍
• 転移性膵臓がん
• 切除可能または切除不可能な腫瘍
• 世界の消化器がん市場、肝がんの種類別サブセグメンテーション、実績と予測、2019年～2024年、2024年～2029年、2034年
• 肝細胞がん（HCC）
• 肝内胆管がん
• 肝芽腫
• 二次性（転移性）肝がん
• 世界の消化器がん市場、その他のがんの種類のサブセグメンテーション、種類別、実績と予測、2019年～2024年、2024年～2029年、2034年
• 小腸がん
• 肛門がん
• 胆嚢がん
• 消化管カルチノイド腫瘍

第7章 地域別・国別分析

• 世界の消化器がん市場：地域別、実績と予測、2019年～2024年、2024年～2029年、2034年
• 世界の消化器がん市場：国別、実績と予測、2019年～2024年、2024年～2029年、2034年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 消化器がん市場：競合情勢
• 消化器がん市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Bayer AG Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Sanofi S.A.
• Bristol-Myers Squibb Company
• AstraZeneca PLC
• Novartis AG
• GlaxoSmithKline plc
• Takeda Pharmaceutical Company Limited
• Eli Lilly and Company
• Amgen Inc.
• Parexel International Corporation
• Ipsen Biopharmaceuticals Inc.
• Exelixis Inc.
• BeiGene Ltd.
• Boehringer Ingelheim International GmbH
• Zai Lab Limited
• Taiho Pharmaceutical Co. Ltd.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 消化器がん市場2029年：新たな機会を提供する国
• 消化器がん市場2029年：新たな機会を提供するセグメント
• 消化器がん市場2029年：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Gastrointestinal (GI) cancer comprises a group of malignancies that affect the digestive organs, including the esophagus, stomach, liver, pancreas, gallbladder, small intestine, colon, and rectum. These cancers occur when abnormal cells begin to grow uncontrollably within the gastrointestinal tract. The primary objectives of GI cancer treatment are to remove or manage the cancer, alleviate associated symptoms, and enhance the patient's quality of life.

The major categories of gastrointestinal cancer include colorectal cancer, stomach cancer, esophageal cancer, pancreatic cancer, liver cancer, and others. Colorectal cancer, which affects the colon or rectum, is largely influenced by genetic predispositions and lifestyle factors, making it suitable for focused screening and specialized treatment approaches in GI oncology. Diagnosis is conducted using techniques such as endoscopy, biopsy, molecular diagnostics, imaging, and more. Treatment options consist of chemotherapy, immunotherapy, targeted therapy, radiation therapy, surgery, and other modalities. These are utilized across various settings, including hospitals, oncology centers, diagnostic labs, research institutions, and others.

The gastrointestinal cancer market research report is one of a series of new reports from The Business Research Company that provides gastrointestinal cancer market statistics, including the gastrointestinal cancer industry global market size, regional shares, competitors with the gastrointestinal cancer market share, detailed gastrointestinal cancer market segments, market trends, opportunities, and any further data you may need to thrive in the gastrointestinal cancer industry. This gastrointestinal cancer market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The gastrointestinal cancer market size has grown rapidly in recent years. It will grow from $24.09 billion in 2024 to $27.05 billion in 2025 at a compound annual growth rate (CAGR) of 12.3%. The expansion during the historic period was fueled by the increasing incidence of GI cancers, heightened tobacco and alcohol use, a rising elderly population, unhealthy dietary patterns, and significant progress in cancer diagnostics and treatment methods.

The gastrointestinal cancer market size is expected to see rapid growth in the next few years. It will grow to $42.45 billion in 2029 at a compound annual growth rate (CAGR) of 11.9%. This anticipated growth is driven by the wider application of biomarker-based therapies, greater public awareness regarding early cancer detection, strengthened healthcare systems, supportive government programs for oncology care, and a rising preference for less invasive treatment techniques. Key market trends projected for this period include advancements in diagnostic technologies, breakthroughs in targeted and immunotherapies, integration of artificial intelligence in cancer management, and continued progress in precision medicine research.

The rising adoption of targeted therapies is expected to propel the growth of the gastrointestinal cancer market going forward. Targeted therapies are treatments that precisely block cancer cell growth by acting on specific molecular targets, reducing harm to normal, healthy cells. These therapies are designed to act on specific molecular pathways or genetic mutations driving a disease, especially in cancer. Unlike traditional treatments like chemotherapy, which attack both healthy and diseased cells, targeted therapies focus on the unique characteristics of a patient's condition. In the case of gastrointestinal (GI) cancer, targeted therapies act on specific genes or proteins that control tumor growth, enabling precise and effective treatment. This approach results in better outcomes with fewer side effects compared to conventional chemotherapy. For instance, in July 2023, according to the American Society of Gene & Cell Therapy (ASGCT), a US-based professional membership organization, and Citeline, a US-based provider of drugs and devices, there were 247 gene therapies in Phase II by the end of quarter one (Q1) 2023, which rose by 5% to reach 260 by the end of quarter two (Q2). Therefore, the rising adoption of targeted therapies is driving the growth of the gastrointestinal cancer market.

Major companies operating in the gastrointestinal cancer market are focused on developing advanced solutions, such as monoclonal antibody treatment, to improve patient survival rates and minimize treatment-related side effects. Monoclonal antibody treatment involves using laboratory-produced antibodies that precisely identify and attach to cancer cells, assisting the immune system in targeting and eliminating them. For instance, in September 2024, Astellas Pharma Inc., a Japan-based pharmaceutical company, launched VYLOY (zolbetuximab) in combination with fluoropyrimidine- and platinum-containing chemotherapy, which received approval from the European Commission. It is a first-line treatment for adults with locally advanced unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma whose tumors express claudin 18.2 (CLDN18.2). This approval makes VYLOY the first and only therapy in the European Union targeting CLDN18.2, a biomarker present in about 38% of these patients, based on positive clinical trial data from the SPOTLIGHT and GLOW studies.

In February 2025, GSK plc, a UK-based pharmaceutical and biotechnology company, acquired IDRx Inc. for approximately $1.15 billion. With this acquisition, GSK aims to strengthen its immunology and infectious disease pipeline, accelerate the development of innovative therapies, and expand its capabilities in precision medicine to better address unmet medical needs. IDRx Inc. is a US-based clinical-stage biopharmaceutical company dedicated to developing precision therapeutics for the treatment of gastrointestinal stromal tumors (GIST).

Major players in the gastrointestinal cancer market are Pfizer Inc., Johnson & Johnson, Roche Holding AG, Merck & Co. Inc., Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Novartis AG, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Parexel International Corporation, Ipsen Biopharmaceuticals Inc., Exelixis Inc., BeiGene Ltd., Boehringer Ingelheim International GmbH, Zai Lab Limited, and Taiho Pharmaceutical Co. Ltd.

North America was the largest region in the gastrointestinal cancer market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in gastrointestinal cancer report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the gastrointestinal cancer market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The gastrointestinal cancer market consists of revenues earned by entities by providing services such as genetic counseling and testing, palliative and supportive care, nutrition and dietary support, rehabilitation services, and follow-up and survivorship programs. The market value includes the value of related goods sold by the service provider or included within the service offering. The gastrointestinal cancer market includes sales of laparoscopic instruments, robotic surgery systems, pain management medications, and monitoring tools. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Gastrointestinal Cancer Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on gastrointestinal cancer market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for gastrointestinal cancer ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The gastrointestinal cancer market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Cancer Type: Colorectal Cancer; Stomach Cancer; Esophageal Cancer; Pancreatic Cancer; Liver Cancer; Other Cancer Types
• 2) By Diagnostics: Endoscopy; Biopsy; Molecular Diagnostics; Imaging; Other Diagnostics
• 3) By Treatment: Chemotherapy; Immunotherapy; Targeted Therapy; Radiation Therapy; Surgery; Other Treatments
• 4) By End-User: Hospitals; Oncology Centers; Research Institutes; Diagnostic Laboratories; Other End-Users
• Subsegments:
• 1) By Colorectal Cancer: Colon Cancer; Rectal Cancer; Recurrent Colorectal Cancer; Metastatic Colorectal Cancer
• 2) By Stomach Cancer: Adenocarcinoma; Gastrointestinal Stromal Tumors (GIST); Lymphoma; Carcinoid Tumors
• 3) By Esophageal Cancer: Adenocarcinoma; Squamous Cell Carcinoma; Small Cell Carcinoma; Other Rare Esophageal Tumors
• 4) By Pancreatic Cancer: Exocrine Pancreatic Cancer; Endocrine (Neuroendocrine) Pancreatic Tumors; Metastatic Pancreatic Cancer; Resectable Or Unresectable Tumors
• 5) By Liver Cancer: Hepatocellular Carcinoma (HCC); Intrahepatic Cholangiocarcinoma; Hepatoblastoma; Secondary (Metastatic) Liver Cancer
• 6) By Other Cancer Types: Small Intestine Cancer; Anal Cancer; Gallbladder Cancer; Gastrointestinal Carcinoid Tumor
• Companies Mentioned: Pfizer Inc.; Johnson & Johnson; Roche Holding AG; Merck & Co. Inc.; Bayer AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Gastrointestinal Cancer Market Characteristics

3. Gastrointestinal Cancer Market Trends And Strategies

4. Gastrointestinal Cancer Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Gastrointestinal Cancer Growth Analysis And Strategic Analysis Framework

• 5.1. Global Gastrointestinal Cancer PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Gastrointestinal Cancer Market Growth Rate Analysis
• 5.4. Global Gastrointestinal Cancer Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Gastrointestinal Cancer Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Gastrointestinal Cancer Total Addressable Market (TAM)

6. Gastrointestinal Cancer Market Segmentation

• 6.1. Global Gastrointestinal Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Colorectal Cancer
• Stomach Cancer
• Esophageal Cancer
• Pancreatic Cancer
• Liver Cancer
• Other Cancer Types
• 6.2. Global Gastrointestinal Cancer Market, Segmentation By Diagnostics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Endoscopy
• Biopsy
• Molecular Diagnostics
• Imaging
• Other Diagnostics
• 6.3. Global Gastrointestinal Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Chemotherapy
• Immunotherapy
• Targeted Therapy
• Radiation Therapy
• Surgery
• Other Treatments
• 6.4. Global Gastrointestinal Cancer Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Oncology Centers
• Research Institutes
• Diagnostic Laboratories
• Other End-Users
• 6.5. Global Gastrointestinal Cancer Market, Sub-Segmentation Of Colorectal Cancer, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Colon Cancer
• Rectal Cancer
• Recurrent Colorectal Cancer
• Metastatic Colorectal Cancer
• 6.6. Global Gastrointestinal Cancer Market, Sub-Segmentation Of Stomach Cancer, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Adenocarcinoma
• Gastrointestinal Stromal Tumors (GIST)
• Lymphoma
• Carcinoid Tumors
• 6.7. Global Gastrointestinal Cancer Market, Sub-Segmentation Of Esophageal Cancer, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Adenocarcinoma
• Squamous Cell Carcinoma
• Small Cell Carcinoma
• Other Rare Esophageal Tumors
• 6.8. Global Gastrointestinal Cancer Market, Sub-Segmentation Of Pancreatic Cancer, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Exocrine Pancreatic Cancer
• Endocrine (Neuroendocrine) Pancreatic Tumors
• Metastatic Pancreatic Cancer
• Resectable Or Unresectable Tumors
• 6.9. Global Gastrointestinal Cancer Market, Sub-Segmentation Of Liver Cancer, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hepatocellular Carcinoma (HCC)
• Intrahepatic Cholangiocarcinoma
• Hepatoblastoma
• Secondary (Metastatic) Liver Cancer
• 6.10. Global Gastrointestinal Cancer Market, Sub-Segmentation Of Other Cancer Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Small Intestine Cancer
• Anal Cancer
• Gallbladder Cancer
• Gastrointestinal Carcinoid Tumors

7. Gastrointestinal Cancer Market Regional And Country Analysis

• 7.1. Global Gastrointestinal Cancer Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Gastrointestinal Cancer Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Gastrointestinal Cancer Market

• 8.1. Asia-Pacific Gastrointestinal Cancer Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Gastrointestinal Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Gastrointestinal Cancer Market, Segmentation By Diagnostics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Gastrointestinal Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Gastrointestinal Cancer Market

• 9.1. China Gastrointestinal Cancer Market Overview
• 9.2. China Gastrointestinal Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Gastrointestinal Cancer Market, Segmentation By Diagnostics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Gastrointestinal Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Gastrointestinal Cancer Market

• 10.1. India Gastrointestinal Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Gastrointestinal Cancer Market, Segmentation By Diagnostics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Gastrointestinal Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Gastrointestinal Cancer Market

• 11.1. Japan Gastrointestinal Cancer Market Overview
• 11.2. Japan Gastrointestinal Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Gastrointestinal Cancer Market, Segmentation By Diagnostics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Gastrointestinal Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Gastrointestinal Cancer Market

• 12.1. Australia Gastrointestinal Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Gastrointestinal Cancer Market, Segmentation By Diagnostics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Gastrointestinal Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Gastrointestinal Cancer Market

• 13.1. Indonesia Gastrointestinal Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Gastrointestinal Cancer Market, Segmentation By Diagnostics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Gastrointestinal Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Gastrointestinal Cancer Market

• 14.1. South Korea Gastrointestinal Cancer Market Overview
• 14.2. South Korea Gastrointestinal Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Gastrointestinal Cancer Market, Segmentation By Diagnostics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Gastrointestinal Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Gastrointestinal Cancer Market

• 15.1. Western Europe Gastrointestinal Cancer Market Overview
• 15.2. Western Europe Gastrointestinal Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Gastrointestinal Cancer Market, Segmentation By Diagnostics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Gastrointestinal Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Gastrointestinal Cancer Market

• 16.1. UK Gastrointestinal Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Gastrointestinal Cancer Market, Segmentation By Diagnostics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Gastrointestinal Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Gastrointestinal Cancer Market

• 17.1. Germany Gastrointestinal Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Gastrointestinal Cancer Market, Segmentation By Diagnostics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Gastrointestinal Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Gastrointestinal Cancer Market

• 18.1. France Gastrointestinal Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Gastrointestinal Cancer Market, Segmentation By Diagnostics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Gastrointestinal Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Gastrointestinal Cancer Market

• 19.1. Italy Gastrointestinal Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Gastrointestinal Cancer Market, Segmentation By Diagnostics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Gastrointestinal Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Gastrointestinal Cancer Market

• 20.1. Spain Gastrointestinal Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Gastrointestinal Cancer Market, Segmentation By Diagnostics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Gastrointestinal Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Gastrointestinal Cancer Market

• 21.1. Eastern Europe Gastrointestinal Cancer Market Overview
• 21.2. Eastern Europe Gastrointestinal Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Gastrointestinal Cancer Market, Segmentation By Diagnostics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Gastrointestinal Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Gastrointestinal Cancer Market

• 22.1. Russia Gastrointestinal Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Gastrointestinal Cancer Market, Segmentation By Diagnostics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Gastrointestinal Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Gastrointestinal Cancer Market

• 23.1. North America Gastrointestinal Cancer Market Overview
• 23.2. North America Gastrointestinal Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Gastrointestinal Cancer Market, Segmentation By Diagnostics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Gastrointestinal Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Gastrointestinal Cancer Market

• 24.1. USA Gastrointestinal Cancer Market Overview
• 24.2. USA Gastrointestinal Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Gastrointestinal Cancer Market, Segmentation By Diagnostics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Gastrointestinal Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Gastrointestinal Cancer Market

• 25.1. Canada Gastrointestinal Cancer Market Overview
• 25.2. Canada Gastrointestinal Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Gastrointestinal Cancer Market, Segmentation By Diagnostics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Gastrointestinal Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Gastrointestinal Cancer Market

• 26.1. South America Gastrointestinal Cancer Market Overview
• 26.2. South America Gastrointestinal Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Gastrointestinal Cancer Market, Segmentation By Diagnostics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Gastrointestinal Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Gastrointestinal Cancer Market

• 27.1. Brazil Gastrointestinal Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Gastrointestinal Cancer Market, Segmentation By Diagnostics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Gastrointestinal Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Gastrointestinal Cancer Market

• 28.1. Middle East Gastrointestinal Cancer Market Overview
• 28.2. Middle East Gastrointestinal Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Gastrointestinal Cancer Market, Segmentation By Diagnostics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Gastrointestinal Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Gastrointestinal Cancer Market

• 29.1. Africa Gastrointestinal Cancer Market Overview
• 29.2. Africa Gastrointestinal Cancer Market, Segmentation By Cancer Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Gastrointestinal Cancer Market, Segmentation By Diagnostics, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Gastrointestinal Cancer Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Gastrointestinal Cancer Market Competitive Landscape And Company Profiles

• 30.1. Gastrointestinal Cancer Market Competitive Landscape
• 30.2. Gastrointestinal Cancer Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Bayer AG Overview, Products and Services, Strategy and Financial Analysis

31. Gastrointestinal Cancer Market Other Major And Innovative Companies

• 31.1. Sanofi S.A.
• 31.2. Bristol-Myers Squibb Company
• 31.3. AstraZeneca PLC
• 31.4. Novartis AG
• 31.5. GlaxoSmithKline plc
• 31.6. Takeda Pharmaceutical Company Limited
• 31.7. Eli Lilly and Company
• 31.8. Amgen Inc.
• 31.9. Parexel International Corporation
• 31.10. Ipsen Biopharmaceuticals Inc.
• 31.11. Exelixis Inc.
• 31.12. BeiGene Ltd.
• 31.13. Boehringer Ingelheim International GmbH
• 31.14. Zai Lab Limited
• 31.15. Taiho Pharmaceutical Co. Ltd.

32. Global Gastrointestinal Cancer Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Gastrointestinal Cancer Market

34. Recent Developments In The Gastrointestinal Cancer Market

35. Gastrointestinal Cancer Market High Potential Countries, Segments and Strategies

• 35.1 Gastrointestinal Cancer Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Gastrointestinal Cancer Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Gastrointestinal Cancer Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer